How I treat relapsed and/or refractory multiple myeloma

The expanding therapeutic landscape of relapsed and/or refractory multiple myeloma (RRMM) has contributed to significant improvements in patient outcomes. These have included combinations of proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), monoclonal antibodies (mAbs), histone deacetylas...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Hans C., Cerchione, Claudio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PAGEPress Publications, Pavia, Italy 2020
Materias:
How to manage - Multiple Myeloma
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7520845/
https://www.ncbi.nlm.nih.gov/pubmed/33042504
http://dx.doi.org/10.4081/hr.2020.8955

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7520845/
https://www.ncbi.nlm.nih.gov/pubmed/33042504
http://dx.doi.org/10.4081/hr.2020.8955

Ejemplares similares